Japan· JP-3999477G1027
ゴリムマブ（遺伝子組換え）［ゴリムマブ後続１］
A medicinal product containing ゴリムマブ（遺伝子組換え）［ゴリムマブ後続１］, registered in Japan by 富士製薬工業, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ゴリムマブ（遺伝子組換え）［ゴリムマブ後続１］
- Manufacturer
- 富士製薬工業
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
ゴリムマブ（遺伝子組換え）［ゴリムマブ後続１］ in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGOBIVAZADVANZ PHARMA Limited, Dublin
- FinlandGobivazAdvanz Pharma Limited
- SwitzerlandGobivaz 100 mg/1 ml, Injektionslösung im FertigpenAdvanz Pharma Specialty Medicine Switzerland GmbH
- BelgiumGobivaz 100 mgAdvanz Pharma
- SwedenGOBIVAZ 100 mg Injektionsvätska, lösning i förfylld injektionspennaAdvanz Pharma Limited
- IcelandGobivazADVANZ PHARMA Limited
- IrelandGOBIVAZ 100 mg solution for injection in pre-filled penAdvanz Pharma Limited
- NetherlandsGOBIVAZ 100 mg oplossing voor injectie in een voorgevulde penAdvanz Pharma Limited
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Gotenfia
- Iceland · Gobivaz, Gotenfia
- Liechtenstein · Gobivaz, Gotenfia
- Norway · Gobivaz, Gotenfia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aaef26aa-cf05-49b6-a9e7-da1fd2e61d9a GET /v1/drugs/aaef26aa-cf05-49b6-a9e7-da1fd2e61d9a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５０ｍｇ０．５ｍＬ１筒",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3999477G1027",
"category": "注射薬",
"price_yen": 8510,
"generic_name": "ゴリムマブ（遺伝子組換え）［ゴリムマブ後続１］",
"product_name_jp": null,
"therapeutic_class": "3999",
"transitional_expiry": "8510"
}See everything about ゴリムマブ（遺伝子組換え）［ゴリムマブ後続１］.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.